이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GoHealth 관리

관리 기준 확인 2/4

GoHealth's CEO는 Vijay Kotte, Jun2022 에 임명되었습니다 의 임기는 2.08 년입니다. 총 연간 보상은 $ 5.14M, 17.5% 로 구성됩니다. 17.5% 급여 및 82.5% 보너스(회사 주식 및 옵션 포함). 는 $ 11.72M 가치에 해당하는 회사 주식의 5.3% 직접 소유합니다. 11.72M. 경영진과 이사회의 평균 재임 기간은 각각 1.5 년과 4.5 년입니다.

주요 정보

Vijay Kotte

최고 경영자

US$5.1m

총 보상

CEO 급여 비율	17.5%
CEO 임기	2.1yrs
CEO 소유권	5.3%
경영진 평균 재임 기간	1.5yrs
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

GoHealth: Turning The Corner On Operating Cash Flow

May 28

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 10

CEO 보상 분석

Vijay Kotte 의 보수는 GoHealth 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$67m
Dec 31 2023	US$5m	US$900k	-US$67m
Sep 30 2023	n/a	n/a	-US$127m
Jun 30 2023	n/a	n/a	-US$132m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$10m	US$485k	-US$150m

보상 대 시장: Vijay 의 총 보상 ($USD 5.14M )은 US 시장( $USD 1.62M ).

보상과 수익: Vijay 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Vijay Kotte (46 yo)

2.1yrs

테뉴어

US$5,141,874

보상

Mr. Vijay Kumar Kotte serves as Chief Executive Officer & Director of GoHealth, Inc. from June 06, 2022. He served as Executive Vice President, Strategy & Corporate Development and Chief Solutions Officer...

리더십 팀

이름	위치	테뉴어	보상	소유권
Brandon Cruz	Co-Founder & Non-Executive Co-Chairman	4.5yrs	US$500.00k	0.070% $ 161.9k
Clinton Jones	Co-Founder & Non-Executive Co-Chairman	4.5yrs	US$500.00k	0.26% $ 594.0k
Vijay Kotte	CEO & Director	2.1yrs	US$5.14m	5.3% $ 12.3m
Michael Hargis	Chief Operating Officer	less than a year	US$2.20m	0.41% $ 953.4k
Jason Schulz	Executive Officer	less than a year	US$1.39m	2.51% $ 5.8m
Katherine M. O'Halloran	Interim CFO & Chief Accounting Officer	1.3yrs	데이터 없음	0.036% $ 82.6k
John Shave	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Bradley Burd	Chief Legal Officer & Corporate Secretary	less than a year	데이터 없음	0.074% $ 171.5k
Stephen Moffat	Chief Marketing Officer	1.5yrs	데이터 없음	데이터 없음
Alison Moriarty	Chief People Officer	1.5yrs	데이터 없음	데이터 없음
Michael Kelley	Chief Actuary & SVP of Strategic Business Insights	1.8yrs	데이터 없음	데이터 없음

1.5yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: GOCO 의 관리팀은 경험 (평균 재직 기간 1.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Brandon Cruz	Co-Founder & Non-Executive Co-Chairman	4.5yrs	US$500.00k	0.070% $ 161.9k
Clinton Jones	Co-Founder & Non-Executive Co-Chairman	4.5yrs	US$500.00k	0.26% $ 594.0k
Vijay Kotte	CEO & Director	2.1yrs	US$5.14m	5.3% $ 12.3m
David Fisher	Independent Director	2.2yrs	US$525.00k	0.69% $ 1.6m
Jeremy Gelber	Independent Director	4.5yrs	데이터 없음	데이터 없음
Alexander Timm	Lead Independent Director	4.5yrs	US$399.99k	0.22% $ 513.1k
Christopher Litchford	Independent Director	1.8yrs	데이터 없음	데이터 없음
Karoline Hilu	Independent Director	1.5yrs	US$355.79k	0.11% $ 247.5k

3.3yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 이사회: GOCO 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

GoHealth 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

GoHealth, Inc. Announces Chief Financial Officer Changes

GoHealth, Inc. Announces Resignation of Jason Schulz as Treasurer

GoHealth, Inc., Annual General Meeting, Jun 12, 2024

GoHealth, Inc. Announces Departure of Shane Cruz, the Current Chief Strategy Officer, Whose Employment Will Terminate as of June 30, 2023

CEO & Director recently bought US$100k worth of stock

Gohealth, Inc. Appoints Karolina Hilu as A Class III Director

Recent updates

New minor risk - Shareholder dilution

New minor risk - Share price stability

New minor risk - Market cap size

GoHealth, Inc. Announces Chief Financial Officer Changes

GoHealth, Inc. Announces Resignation of Jason Schulz as Treasurer

GoHealth: Turning The Corner On Operating Cash Flow

First quarter 2024 earnings released: US$0.95 loss per share (vs US$1.12 loss in 1Q 2023)

GoHealth, Inc., Annual General Meeting, Jun 12, 2024

GoHealth, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 18%

Robbins Geller Rudman & Dowd LLP Announces a Notice of Pendency and Proposed Settlement of Class Action in the GoHealth, Inc. Securities Litigation

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$3.40 loss per share (vs US$17.72 loss in FY 2022)

GoHealth, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Price target increased by 43% to US$20.00

GoHealth, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Group of buyers cancelled the acquisition of remaining stake in GoHealth, Inc. (NasdaqCM:GOCO).

GoHealth, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GoHealth, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates fall by 17%

GoHealth, Inc. Announces Departure of Shane Cruz, the Current Chief Strategy Officer, Whose Employment Will Terminate as of June 30, 2023

Price target increased by 31% to US$14.02

Group of buyers submitted a non-binding proposal to acquire remaining stake in GoHealth, Inc. (NasdaqCM:GOCO) for approximately $330 million.

CEO & Director recently bought US$100k worth of stock

Consensus EPS estimates upgraded to US$3.74 loss

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

GoHealth, Inc. Reiterates Earnings Guidance for the Year 2023

Consensus revenue estimates decrease by 15%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 34%

Consensus EPS estimates fall by 37%

Gohealth, Inc. Appoints Karolina Hilu as A Class III Director

Consensus forecasts updated

GoHealth, Inc. Receives Extension Notice from Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

GoHealth, Inc. to Report Q3, 2022 Results on Nov 10, 2022

GoHealth stock jumps 11% premarket on $50M private investment

GoHealth, Inc. announced delayed 10-Q filing

Price target decreased to US$1.10

GoHealth, Inc. to Report Q2, 2022 Results on Aug 15, 2022

GoHealth, Inc. Appoints Shane Cruz as Chief Strategy Officer

GoHealth, Inc. Names Jason Schulz as Chief Financial Officer

High number of new and inexperienced directors

GoHealth, Inc. Announces Executive Changes

GoHealth, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

GoHealth, Inc., Annual General Meeting, May 25, 2022

GoHealth, Inc. Announces the Resignation of Anita Pramoda from the Board of Directors

GoHealth, Inc. announced delayed annual 10-K filing

Consensus EPS estimates fall by 68%

GoHealth, Inc. Provides Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2021

Price target decreased to US$4.25

GoHealth: Painful Competition, Cost Controls Are Key

Price target decreased to US$5.79

GoHealth Looks To Q4 For Submission Growth

Co-Founder recently bought US$1.9m worth of stock

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.65 loss in 3Q 2020)

Price target decreased to US$8.50

Independent Director Rahm Emanuel has left the company

GoHealth: Post Sell-Off, A Fresh Look

Co-Founder recently bought US$1.2m worth of stock

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.002 profit in 2Q 2020)

GoHealth, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2021

Price target decreased to US$15.89

Chief Operating Officer exercised options and sold US$703k worth of stock

GoHealth amends credit agreement, lowers the interest rate to 4%